A phase II trial of dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Mey, UJM
Strehl, JW
Orlopp, KS
Flieger, D
Birkmann, J
Ho, A
Kaiser, U
Neubauer, A
Glasmacher, AG
Schmidt-Wolf, IGH
机构：
[1] Univ Bonn, Dept Internal Med 1, D-5300 Bonn, Germany
[2] Klinikum Aschaffenburg, Dept Internal Med 2, Aschaffenburg, Germany
[3] Univ Erlangen Nurnberg, Dept Internal Med 5, Nurnberg, Germany
[4] Univ Heidelberg, Dept Internal Med 5, Heidelberg, Germany
[5] St Bernward Krankenhaus, Dept Internal Med 2, Hildesheim, Germany
[6] Univ Marburg, Dept Internal Med, Marburg, Germany
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4618
引用
收藏
页码：238B / 238B
页数：1
相关论文
共 50 条
  • [1] Dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
    Mey, U
    Orlopp, K
    Flieger, D
    Strehl, J
    Ho, A
    Hensel, M
    Birkmann, J
    Wilhelm, M
    Kaiser, U
    Neubauer, A
    Glasmacher, A
    Schmidt-Wolf, I
    [J]. ANNALS OF ONCOLOGY, 2005, 16 : 180 - 180
  • [2] Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma
    Mey, Ulrich J. M.
    Orlopp, Katjana S.
    Flieger, Dimitri
    Strehl, John W.
    Ho, Anthony D.
    Hensel, Manfred
    Bopp, Cordula
    Gorschlueter, Marcus
    Wilhelm, Martin
    Birkmann, Josef
    Kaiser, Ulrich
    Neubauer, Andreas
    Florschuetz, Axel
    Rabe, Christian
    Hahn, Corinna
    Glasmacher, Axel G.
    Schmidt-Wolf, Ingo G. H.
    [J]. CANCER INVESTIGATION, 2006, 24 (06) : 593 - 600
  • [3] Dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab as salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma: Updated results of a multicenter phase II trial.
    Mey, UJM
    Flieger, D
    Birkmann, J
    Neubauer, A
    Ho, AD
    Kaiser, U
    Wilhelm, M
    Haarmann, G
    Hahn, C
    Strehl, JW
    Glasmacher, AG
    Schmidt-Wolf, IGH
    [J]. BLOOD, 2003, 102 (11) : 300B - 301B
  • [4] Salvage treatment for patients with refractory or relapsed aggressive non-Hodgkin's lymphoma with dexamethasone, high-dose cytarabine, and cisplatin (DHAP) in combination with rituximab: Preliminary results of a multicenter phase it trial.
    Mey, U
    Flieger, D
    Birkmann, J
    Ho, A
    Huhn, D
    Kaiser, U
    Ko, Y
    Kraemer, A
    Neubauer, A
    Wilhelm, M
    Hahn, C
    Haarmann, G
    Glasmacher, A
    Schmidt-Wolf, I
    [J]. BLOOD, 2002, 100 (11) : 309B - 309B
  • [5] Dexamethasone, high-dose cytarabine, and oxaliplatin (DHAOx) as salvage treatment for patients with initially refractory or relapsed non-Hodgkin's lymphoma
    Machover, D
    Delmas-Marsalet, B
    Misra, SC
    Gumus, Y
    Goldschmidt, E
    Schilf, A
    Frénoy, N
    Emile, JF
    Debuire, B
    Guettier, C
    Farrokhi, P
    Boulefdaoui, B
    Norol, F
    Parquet, N
    Ulusakarya, A
    Jasmin, C
    [J]. ANNALS OF ONCOLOGY, 2001, 12 (10) : 1439 - 1443
  • [6] A phase II trial of Rituximab plus ESHAP as salvage chemotherapy in relapsed/refractory aggressive histology non-Hodgkin's lymphoma.
    Piliotis, EG
    Mangel, J
    Buckstein, R
    Imrie, K
    Spaner, D
    Reis, M
    Foden, C
    Boudreau, A
    Richardson, P
    Richardson, J
    Berinstein, N
    [J]. BLOOD, 2003, 102 (11) : 288B - 288B
  • [7] A Multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin (ESHAOx) for patients with refractory/relapsed aggressive non-Hodgkin's lymphoma
    Sym, Sun Jin
    Kang, Hye Jin
    Nam, Seung-Hyun
    Kim, Hoyoung
    Kim, Seok Jin
    Eom, Hyeon Seok
    Kim, Won Seog
    Suh, Cheolwon
    [J]. BLOOD, 2007, 110 (11) : 1010A - 1010A
  • [8] Phase II study of a salvage regimen using cyclophosphamide, high-dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma
    Oki, Yasuhiro
    Ogura, Michinori
    Kato, Harumi
    Kikuchi, Ako
    Taji, Hirofumi
    Kagami, Yoshitoyo
    Oshiro, Aya
    Tsujimura, Akane
    Yamamoto, Kazuhito
    Morishima, Yasuo
    [J]. CANCER SCIENCE, 2008, 99 (01) : 179 - 184
  • [9] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin’s lymphoma
    Sun Jin Sym
    Dae Ho Lee
    Hye Jin Kang
    Seung Hyun Nam
    Ho Young Kim
    Seok Jin Kim
    Hyeon Seok Eom
    Won Seog Kim
    Cheolwon Suh
    [J]. Cancer Chemotherapy and Pharmacology, 2009, 64 : 27 - 33
  • [10] A multicenter phase II trial of etoposide, methylprednisolone, high-dose cytarabine, and oxaliplatin for patients with primary refractory/relapsed aggressive non-Hodgkin's lymphoma
    Sym, Sun Jin
    Lee, Dae Ho
    Kang, Hye Jin
    Nam, Seung Hyun
    Kim, Ho Young
    Kim, Seok Jin
    Eom, Hyeon Seok
    Kim, Won Seog
    Suh, Cheolwon
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 64 (01) : 27 - 33
12345